{{redirect|Yoman|the film called "Yoman" in Hebrew|Diary (1983 film)}}
{{Drugbox
| verifiedrevid = 470634701
| IUPAC_name = 17α-hydroxy-yohimban-16α-<br />carboxylic acid methyl ester
| image = Yohimbine structure.svg
| image2 = Yohimbine-3D-balls-Trans.png

<!--Clinical data-->
| pregnancy_category =  
| legal_AU = S4
| legal_US_comment = [[Dietary supplement]]
| routes_of_administration = [[Oral route|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 7-86% (mean 33%)
| metabolism =  
| excretion = Urine (as metabolites)
| elimination_half-life = 0.25-2.5 hours<ref>{{cite journal|title=Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers|journal=European Journal of Clinical Pharmacology|year=1992|volume=43|issue=6|pages=651–656|pmid=1493849|doi=10.1007/BF02284967|author1=Hedner, T |author2=Edgar, B |author3=Edvinsson, L |author4=Hedner, J |author5=Persson, B |author6=Pettersson, A }}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 146-48-5
| ATC_prefix = G04
| ATC_suffix = BE04
| ATC_supplemental = {{ATCvet|V03|AB93}}
| PubChem = 8969
| IUPHAR_ligand = 102
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01392
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8622
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2Y49VWD90Q
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 10093
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 15245

<!--Chemical data-->
| C=21 | H=26 | N=2 | O=3
| molecular_weight = 354.44 g/mol (base)<br />390.90 g/mol (hydrochloride)
| smiles = O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BLGXFZZNTVWLAY-SCYLSFHTSA-N
}}

'''Yohimbine''' ({{IPAc-en|j|ou|'|h|I|m|b|i:|n}})<ref>yohimbine. (n.d.) Collins English Dictionary – Complete and Unabridged. (1991, 1994, 1998, 2000, 2003). Retrieved January 27, 2015 from http://www.thefreedictionary.com/yohimbine</ref> is an [[indole alkaloid]] derived from the bark of the [[Pausinystalia yohimbe]] tree in Central Africa. It is a veterinary drug used to reverse sedation in dogs and deer.  Yohimbine has been studied as a potential treatment for [[erectile dysfunction]] but there is insufficient evidence to rate its effectiveness.<ref name=pharmrev/>  Extracts from yohimbe have been marketed as dietary supplements for improving sexual function.<ref name=EFSA2013>{{cite journal|author=Beille, P. E.|journal=[[EFSA Journal]] |title=Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe) |year=2013 |volume=11|issue=7 |doi=10.2903/j.efsa.2013.3302 |page=3302}}</ref>

==Uses==
Yohimbine is a drug used in veterinary medicine to reverse the effects of [[xylazine]] in dogs and deer.<ref>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=522.2670 21 CFR Sec. 522.2670 Yohimbine]</ref>

Yohimbe extracts, which contain yohimbine, have been used in [[traditional medicine]] and marketed as dietary supplements.<ref name=EFSA2013/>

==Toxicity==
Depending on dosage, yohimbine can either increase or decrease systemic blood pressure (through [[vasoconstriction]] or [[vasodilation]], respectively). Because yohimbine has highest affinity for the α<sub>2</sub> receptor, small doses can increase blood pressure by causing a relatively selective α<sub>2</sub> blockade. Yohimbine also, however, interacts with α<sub>1</sub> receptors, albeit with lower affinity; therefore, at higher doses an α<sub>1</sub> blockade can occur and overwhelm the effects of the α<sub>2</sub> blockade, leading to a potentially dangerous drop in blood pressure.<ref name="MedlineSupplement">{{cite web|url=https://nccih.nih.gov/health/yohimbe|title=Yohimbe  Supplement|last=|first=|date=|website=|publisher=National Center for Complementary and Integrative Health|archive-url=|archive-date=|dead-url=|accessdate=2017-08-28}} </ref>
Higher doses of oral yohimbine may create numerous side effects, such as [[tachycardia|rapid heart rate]], overstimulation, anomalous blood pressure, cold sweating, and [[insomnia]].

==Extracts and chemistry==
Yohimbe (''[[Pausinystalia johimbe]]'') is a tree that grows in western and central [[Africa]];<ref name="princessleia">[http://apps.kew.org/wcsp/namedetail.do?name_id=148191 Kew World Checklist of Selected Plant Families, Pausinystalia johimbe ]</ref> yohimbine was originally extracted from the bark of yohimbe in 1896 by Adolph Spiegel.<ref>{{cite book |title=Year Book of the American Pharmaceutical Association|publisher=American Pharmaceutical Association |url=http://www.mocavo.com/Year-Book-of-the-American-Pharmaceutical-Association-1914-Volume-3/874094/565?browse=true#632|page=564 |date=1914 |access-date=2015-05-04 }}</ref>  In 1943 the correct constitution of yohimbine was proposed by Witkop.<ref name="Witkop1943">{{cite journal|last1=Witkop|first1=Bernhard|title=Zur Konstitution des Yohimbins und seiner Abbauprodukte|journal=Justus Liebig's Annalen der Chemie|volume=554|issue=1|year=1943|pages=83–126|issn=00754617|doi=10.1002/jlac.19435540108}}</ref> Fifteen years later, [[Eugene van Tamelen|Van Tamelen]] used a 23-step synthesis to become the first person to achieve the synthesis of yohimbine.<ref>{{cite book|title=The Alkaloids: Chemistry and Pharmacology|last=Liebig|first=Justus|date=1988|publisher=Academic Press|year=|isbn=0-12-469532-9|location=|page=564|pages=}}</ref><ref>{{cite journal |author1=van Tamelen |author2=E. E. |journal=[[J. Am. Chem. Soc.]] |title=The Total Synthesis of Yohimbine |year=1958 |volume=80|issue=18 |pages=5006–5007 |doi=10.1021/ja01551a062}}</ref><ref>{{cite journal |author=Herle, B. |journal=[[J. Org. Chem.]] |title=Total Synthesis of (+)-Yohimbine via an Enantioselective Organocatalytic Pictet–Spengler Reaction |year=2011 |volume=76|issue=21 |pages=8907–8912 |doi=10.1021/jo201657n}}</ref>

== Pharmacology ==
Yohimbine has high [[affinity (pharmacology)|affinity]] for the [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic receptor]], moderate affinity for the [[alpha-1 adrenergic receptor|α<sub>1</sub> receptor]], [[5-HT1A|5-HT<sub>1A</sub>]], [[5-HT1B|5-HT<sub>1B</sub>]], [[5-HT1D|5-HT<sub>1D</sub>]], [[5-HT1F|5-HT<sub>1F</sub>]], [[5-HT2B|5-HT<sub>2B</sub>]], and [[D2 receptor|D<sub>2</sub> receptor]]s, and weak affinity for the [[5-HT1E|5-HT<sub>1E</sub>]], [[5-HT2A|5-HT<sub>2A</sub>]], [[5-HT5A|5-HT<sub>5A</sub>]], [[5-HT7|5-HT<sub>7</sub>]], and [[D3 receptor|D<sub>3</sub> receptor]]s.<ref name="pmid10611634">{{cite journal |author=Millan MJ |title=Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states |journal=Synapse |volume=35 |issue=2 |pages=79–95 |date=February 2000  |pmid=10611634 |doi=10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X |name-list-format=vanc|author2=Newman-Tancredi A |author3=Audinot V |display-authors=3 |last4=Cussac |first4=Didier |last5=Lejeune |first5=Françoise |last6=Nicolas |first6=Jean-Paul |last7=Cog |first7=Francis |last8=Galizzi |first8=Jean-Pierre |last9=Boutin |first9=Jean A.}}</ref><ref name="urlPDSP Ki Database">{{cite web | url = http://pdsp.med.unc.edu/pdsp.php#search | title = PDSP Ki Database}}</ref> It behaves as an [[receptor antagonist|antagonist]] at α<sub>1</sub>-adrenergic, α<sub>2</sub>-adrenergic, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and D<sub>2</sub>, and as a [[partial agonist]] at 5-HT<sub>1A</sub>.<ref name="pmid10611634"/><ref name="pmid8517875">{{cite journal |vauthors=Arthur JM, Casañas SJ, Raymond JR | title = Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 45 | issue = 11 | pages = 2337–41 | date =June 1993  | pmid = 8517875 | doi = 10.1016/0006-2952(93)90208-E| url = }}</ref><ref name="pmid6136920">{{cite journal | author = Kaumann AJ | title = Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 323 | issue = 2 | pages = 149–54 | date =June 1983   | pmid = 6136920 | doi = 10.1007/BF00634263| url = }}</ref><ref name="pmid8032658">{{cite journal |vauthors=Baxter GS, Murphy OE, Blackburn TP | title = Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle | journal = [[British Journal of Pharmacology]] | volume = 112 | issue = 1 | pages = 323–31 | date =May 1994   | pmid = 8032658 | pmc = 1910288 | doi = 10.1111/j.1476-5381.1994.tb13072.x| url =}}</ref> Yohimbine interacts with serotonin and dopamine receptors in high concentrations.<ref>{{cite web|url=http://www.inchem.org/documents/pims/pharm/yohimbin.htm |title=Yohimbine (PIM 567) |publisher=Inchem.org |accessdate=2013-05-26}}</ref>
{| class="wikitable sortable"
|+Pharmacologic profile
|-
! Molecular target !! [[Binding affinity]]<br />(K<sub>i</sub> in [[nanomolar]])<ref>{{cite web|last=National Institute of Mental Health |title=PDSP Ki Database |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina |accessdate=5 July 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=November 8, 2013 }}</ref> !! Pharmacologic action<br /><ref name="pmid10611634"/><ref name="pmid8517875"/><ref name="pmid6136920"/><ref name="pmid8032658"/><ref>{{cite web|title=Yohimbine |url=http://www.drugbank.ca/drugs/DB01392 |work=DrugBank |publisher=University of Alberta |accessdate=12 April 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20130130101146/http://www.drugbank.ca/drugs/DB01392 |archivedate=January 30, 2013 }}</ref>  !! Species !! Source
|-
| [[Serotonin transporter|SERT]] || 1,000 || Inhibitor || Human || Frontal cortex
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 346 || Partial agonist || Human || Cloned
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || 19.9 || Antagonist || Human || Cloned
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || 44.3 || Antagonist || Human || Cloned
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || 1,264 || Unknown || Human || Cloned
|-
| [[5-HT1F receptor|5-HT<sub>1F</sub>]] || 91.6 || Unknown || Human || Cloned
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 1,822 || Antagonist || Human || Cloned
|-
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || 143.7 || Antagonist || Human || Cloned
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 2,850 || Unknown || Human || Cloned
|-
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 1,680 || Antagonist || Human || Cloned
|-
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || 1,280 || Antagonist || Human || Cloned
|-
| [[Alpha-1C adrenergic receptor|α<sub>1C</sub>]] || 770 || Antagonist || Human || Cloned
|-
| [[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] || 557 || Antagonist || Human || Cloned
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 1.05 || Antagonist || Human || Cloned
|-
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 1.19 || Antagonist || Human || Cloned
|-
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 1.19 || Antagonist || Human || Cloned
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 339 || Antagonist || Human || Cloned
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 3,235 || Antagonist|| Human || Cloned
|}

==Research==

=== Sexual dysfunction ===
{{main|Sexual dysfunction}}
Yohimbine has been studied as a potential treatment for [[erectile dysfunction]] but there is insufficient evidence to rate its effectiveness.<ref name=MedlineSupplement/><ref name=pharmrev>{{cite journal |author=Andersson KE |title=Pharmacology of penile erection |journal=Pharmacological Reviews |volume=53 |issue=3 |pages=417–50 |date=September 2001 |pmid=11546836 |url= http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11546836}}</ref>  It is illegal in the United States to market an over the counter product containing yohimbine as a treatment for erectile dysfunction without getting FDA approval to do so.<ref>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=310&showfr=1 FDA regulations on OTC products]</ref>

Yohimbine blocks the pre- and post-synaptic [[alpha-2 adrenoceptors|α<sub>2</sub> receptors]]. Blockade of post-synaptic α<sub>2</sub> receptors causes only minor [[Corpus cavernosum penis|corpus cavernosum]] [[smooth muscle]] relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α<sub>1</sub> type. Blockade of pre-synaptic α<sub>2</sub> receptors facilitates the release of several neurotransmitters in the central and peripheral [[nervous system]] — thus in the corpus cavernosum — such as [[nitric oxide]] and [[norepinephrine]]. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of [[Alpha-1 adrenergic receptors|α<sub>1</sub> receptors]] on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction.<ref name="Pmid">{{cite journal |pmid=10845761 |year=2000 |last1=Saenz De Tejada |first1=I |last2=Kim |first2=NN |last3=Goldstein |first3=I |last4=Traish |first4=AM |title=Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum |volume=12 Suppl 1 |pages=S20–25 |journal=International Journal of Impotence Research |doi=10.1038/sj.ijir.3900500}}</ref>

== See also ==
* [[Ajmalicine]]
* [[Corynanthine]]
* [[Deserpidine]]
* [[Mitragynine]]
* [[Rauwolscine]]
* [[Spegatrine]]
* [[Reserpine]]
* [[Rescinnamine]]

== References ==
{{reflist|30em}}

{{Drugs for erectile dysfunction and PE}}
{{Stimulants}}
{{Serotonergics}}

[[Category:Alpha blockers]]
[[Category:Entheogens]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Anxiogenics]]
[[Category:Indole alkaloids]]
[[Category:Alkaloids found in Rauvolfia]]
[[Category:Alkaloids found in Euphorbiaceae]]
[[Category:Vasodilators]]
[[Category:Vasoconstrictors]]